Business, energy, technology, markets and global industry news from Business News Today

hNPC01

PharmaDeviceNews hNPC01
Representative image: Researchers examine brain imaging and neural cell preparations as Hopstem’s hNPC01 receives FDA clearance for clinical trials targeting chronic motor disability after hemorrhagic stroke and traumatic brain injury.
Pharma & Biotech

FDA clears hNPC01 neural cell therapy trials for hemorrhagic stroke and traumatic brain injury

FDA clears Hopstem’s hNPC01 neural cell therapy for trials in hemorrhagic stroke and traumatic brain injury, with Fast Track status in both.

Read More